闡述我國藥品審評改革中藥品技術(shù)轉(zhuǎn)讓政策帶來的思考。分析藥品注冊申請過程中,科研機(jī)構(gòu)、高校、企業(yè)等主體各階段轉(zhuǎn)讓時機(jī)與策略的選擇與面臨的風(fēng)險和利益。建議科研機(jī)構(gòu)、高校、企業(yè)等各主體應(yīng)結(jié)合政策、市場與自身特點(diǎn)選擇適當(dāng)?shù)霓D(zhuǎn)讓時機(jī)與策略。

The thought of drugs technology transfer policies in the drug review system reform of China was elaborated. The drug registration application process was analyzed, the risks and benefits were gained by research institutes, universities, enterprises, and other stage selection in the pharmaceutical technology transfer timing. Scientific research institutions, universities, and enterprises should be combined with policies and market of their own characteristics and the appropriate timing and transfer policy were selected.

2014年度黑龍江省社會科學(xué)研究規(guī)劃年度項目(14B017);2014年度黑龍江省應(yīng)用技術(shù)研究與開發(fā)計劃項目(GB14D410)。